Drugs / gavocabtagene autoleucel
gavocabtagene autoleucel
English name Gavocabtagene autoleucel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03907852 | Apr 2019 → Nov 2024 overdue | cholangiocarcinoma, malignant mesothelioma, non-small cell lung carcinoma, ovarian serous adenocarcinoma +2 | TCR2 Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gavocabtagene autoleucel | “The T cell receptor fusion construct (TRuC) gavocabtagene autoleucel (gavo-cel) consists of single-domain anti-mesothelin antibody that integrates into the endogenous T cell...” PMID 37501016 ↗ Jul 2023 |
| Known as | gavo-cel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03907852 ↗ |
| Known as | TC-210 T cells | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802259 ↗ |
| Modality | Cell therapy | “Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that...” NCT03907852 ↗ |